Evidence map›Paper›PMID 33025343›Full record

ArticleClinical journal of gastroenterology2021

Colitis induced by Lenvatinib in a patient with advanced hepatocellular carcinoma.

Saori Miyajima, Kunihiro Tsuji, Yosuke Kito, Naohiro Yoshida, Kazuhiro Matsunaga, Shigetsugu Tsuji, Kazuyoshi Katayanagi, Miwa Yonezawa, Anna Kubo, Kahori Ushijima and 2 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Clinical journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Pralsetinib-Induced Lymphocytic Colitis.ACG case reports journal · 2026
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Saori MiyajimaDepartments of Gastroenterology, Ishikawa Prefectural Central Hospital, 2-1 Kuratukihigashi, Kanazawa, Ishikawa, 920-8530, Japan.ORCID http://orcid.org/0000-0002-6514-6647
Kunihiro TsujiDepartments of Gastroenterology, Ishikawa Prefectural Central Hospital, 2-1 Kuratukihigashi, Kanazawa, Ishikawa, 920-8530, Japan. kt98052@yahoo.co.jp.
Yosuke KitoDepartments of Gastroenterology, Ishikawa Prefectural Central Hospital, 2-1 Kuratukihigashi, Kanazawa, Ishikawa, 920-8530, Japan.
Naohiro YoshidaDepartments of Gastroenterology, Ishikawa Prefectural Central Hospital, 2-1 Kuratukihigashi, Kanazawa, Ishikawa, 920-8530, Japan.
Kazuhiro MatsunagaDepartments of Gastroenterology, Ishikawa Prefectural Central Hospital, 2-1 Kuratukihigashi, Kanazawa, Ishikawa, 920-8530, Japan.
Shigetsugu TsujiDepartments of Gastroenterology, Ishikawa Prefectural Central Hospital, 2-1 Kuratukihigashi, Kanazawa, Ishikawa, 920-8530, Japan.
Kazuyoshi KatayanagiDepartments of Pathology, Ishikawa Prefectural Central Hospital, Ishikawa, Japan.
Miwa YonezawaDepartments of Pharmacy, Ishikawa Prefectural Central Hospital, Ishikawa, Japan.
Anna KuboDepartments of Pharmacy, Ishikawa Prefectural Central Hospital, Ishikawa, Japan.
Kahori UshijimaDepartments of Pharmacy, Ishikawa Prefectural Central Hospital, Ishikawa, Japan.
Hiroshi MinatoDepartments of Pathology, Ishikawa Prefectural Central Hospital, Ishikawa, Japan.
Hisashi DoyamaDepartments of Gastroenterology, Ishikawa Prefectural Central Hospital, 2-1 Kuratukihigashi, Kanazawa, Ishikawa, 920-8530, Japan.
Ishikawa Prefectural Central Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lenvatinib is a standard molecular targeted agent for the first-line treatment of unresectable hepatocellular carcinoma. Here, we report a case of colitis induced by Lenvatinib treatment in a patient with hepatocellular carcinoma. A 78-year-old man previously treated with Lenvatinib for unresectable hepatocellular carcinoma was admitted to our hospital complaining of right lateral abdominal pain without diarrhea. Our endoscopic findings showed multiple ulcers and erosions on his ascending colon, and he was diagnosed with colitis induced by Lenvatinib treatment. After the discontinuation of Lenvatinib, his colitis improved, and he resumed Lenvatinib at a lower dose. Colitis is a rare adverse event of Lenvatinib, and this is the first detailed report of colitis induced by Lenvatinib with endoscopic findings.

Indexed as

Carcinoma, HepatocellularColitisLiver NeoplasmsAgedHumansMalePhenylurea CompoundsQuinolineslenvatinibPhenylurea CompoundsQuinolinesColitisHepatocellular carcinomaLenvatinibMultikinase inhibitor

Identifiers

PMID33025343
OpenAlexW3092050438

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.